In a world in which we need to collaborate in groups to be successful as individuals, understanding how to engage with small and large companies, with institutions and patient advocacy organisations has become increasingly important. But it’s not easily done. Despite the non-silo thinking, there are still hurdles to the adoption of new innovative practices and technologies. Is Big Pharma unable to adopt new practices and techniques because of its existing infrastructure? What lessons can we learn from more agile, rapidly growing companies? What can biotech companies learn from Big Pharma — and vice versa — that can be adapted to their specific environments to foster an atmosphere of more liberal thinking?